In the News
For the 5th year in a row, Rakesh Jain was named a Highly Cited Researcher by Clarivate Analytics / Web of Science. His research ranks among the top 1% most cited works in clinical medicine.
National Foundation for Cancer Research
Promising approach helps drugs cross blood brain barrier, penetrate abnormal tumor tissues and blood vessels
Dr. Shuichi Aoki was awarded the 2018 Tommy J. West Memorial Research Fellowship by the Cholangiocarcinoma Foundation for the project "Role of PlGF/Nrp1 Pathway in Intrahepatic Cholangiocarcinoma Cell Survival, Tumor-associated Fibrosis and Abnormal Vasculature".
Molecular signatures of anti-angiogenic resistant cells could provide new treatment targets.
Read Press Release
They haven’t seen each other in about a year and a half, but once they’ve shaken hands, their conversation immediately turns to science. When your work has the potential to save millions of lives, that’s what you do.
Rakesh K. Jain, COE74M, 76PhD, has spent decades working on some of the world’s most pressing health problems, and has come to be regarded as one of America’s most accomplished scientists. Arup K. Chakraborty, COE88PhD, is tackling one of the world’s most elusive challenges: creating a vaccine for the human immunodeficiency virus (HIV), the causative agent of AIDS.
Read the full story at University of Delaware ...
If confirmed in human patients, findings could indicate the need to treat lymph node metastases
A study by Massachusetts General Hospital (MGH) investigators finds that, in mouse models, cancer cells from metastatic lymph nodes can escape into the circulation by invading nodal blood vessels, leading to the development of metastases in other parts of the body. Their report appearing in the March 23 issue of Science adds evidence to the debate regarding the role of lymph node metastases in the spread of cancer.
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2
Bacterial toxins kill lymphatic muscle cells, raising risk of recurrent infection
Cancer drug targets molecular pathway contributing to tumor progression, radiation-induced hearing loss